A 2025 benefits estimate described GLP-1 prescriptions as a major driver of employer health-plan cost growth

A 2025 benefits estimate described GLP-1 prescriptions as a major driver of employer health-plan cost growth. The accountable actors were employers, insurers, and pharmacy-benefit systems that had to absorb a recurring medicine into annual benefit budgets.

For workers, plan-level cost pressure can show up indirectly through premiums, coverage limits, or utilization rules rather than as a visible change in the medicine itself. That is why a highly discussed product can become an access issue even for people who never use it.

The estimate was a forecast, not a final accounting or a measure of individual value. Drug prices, enrollment, negotiated rebates, and coverage policies can all change the result.

Read the full story at Forbes ↗